Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Sacituzumab Govitecan Plus EV in Metastatic UC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
- Status
- RECRUITING
- Phase
- PHASE2
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
- Status
- COMPLETED
- Phase
- PHASE2
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- Status
- COMPLETED
- Phase
- PHASE3
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
- Status
- RECRUITING
- Phase
- PHASE1
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2